News stories about Cutera (NASDAQ:CUTR) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cutera earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 45.5238234271207 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Several equities analysts have recently issued reports on CUTR shares. Maxim Group reaffirmed a “hold” rating on shares of Cutera in a research note on Wednesday, November 8th. Roth Capital upped their price target on Cutera from $41.00 to $47.00 and gave the company a “buy” rating in a research note on Tuesday, September 12th. Zacks Investment Research lowered Cutera from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. Finally, BidaskClub raised Cutera from a “hold” rating to a “buy” rating in a research note on Tuesday, December 12th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $37.33.
Cutera (NASDAQ:CUTR) opened at $46.20 on Friday. Cutera has a one year low of $16.65 and a one year high of $48.95. The stock has a market capitalization of $635.94, a price-to-earnings ratio of 59.23, a PEG ratio of 1.99 and a beta of 0.53.
In related news, Director David B. Apfelberg sold 1,000 shares of the firm’s stock in a transaction on Wednesday, October 18th. The stock was sold at an average price of $39.90, for a total transaction of $39,900.00. Following the sale, the director now owns 10,259 shares of the company’s stock, valued at approximately $409,334.10. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Timothy J. Oshea sold 4,000 shares of the firm’s stock in a transaction on Monday, October 16th. The shares were sold at an average price of $39.21, for a total value of $156,840.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 24,950 shares of company stock worth $1,085,720. Corporate insiders own 11.60% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Cutera (CUTR) Share Price” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.com-unik.info/2017/12/23/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-cutera-cutr-share-price.html.
Cutera Company Profile
Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.
Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.